gastric cancer with peritoneal metastasis
Conditions
Interventions
Docetaxel is administered intraperitoneally at 10 mg/m2 on days 1 and 8. Capecitabine is administered at 2,000 mg/m2/day for 14 consecutive days, followed by 7 days rest. Cisplatin is administered
Sponsors
The University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Histologically proven unresectable gastric adenocarcinoma with peritoneal metastasis; age between 20 and 75 years; Eastern Cooperative Oncology Group performance status 0-1; adequate bone marrow function (leukocyte count LLN-12,000/mm3, hemoglobin >8.0 g/dl, platelet count >100,000/mm3); adequate liver function (total serum bilirubin <ULNx1.5, serum transaminases <100/UI); adequate renal function (creatinine clearance >60mL/min); and an expected survival period of more than 3 months.
Exclusion criteria
Exclusion criteria: Metastasis to distant organ sites (such as the liver, lungs or bone), other active concomitant malignancies, or other severe medical conditions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| response rate negative conversion rate on peritoneal cytology safety | — |
Countries
Japan
Contacts
Public ContactHironori Ishigami
The University of Tokyo Department of Chemotherapy
Outcome results
None listed